Treating Brain Metastases from Breast Cancer: Outcomes after Stereotactic Radiosurgery.

Clinical Oncology : a Journal of the Royal College of Radiologists
T G WilsonJ P Braybrooke

Abstract

Stereotactic radiosurgery (SRS) is an alternative to surgery or whole brain radiotherapy for the control of single or multiple brain metastases in patients with breast cancer. To date, there is no clear consensus on factors that might predict overall survival following SRS. The aim of this study was to assess the overall survival of breast cancer patients with brain metastases treated with SRS at a single centre and to examine the factors that might influence survival. A retrospective analysis of consecutive patients with breast cancer and brain metastases, considered suitable for SRS by the regional neuro-oncology multidisciplinary team. All patients were treated at a single National Health Service centre. In total, 91 patients received SRS between 2013 and 2017, of whom 15 (16.5%) were alive at the time of analysis. The median overall survival post-SRS was 15.7 months (interquartile range 7.7-23.8 months) with no significant effect of age on survival (67 patients ≤ 65 years, 16.3 months; 26 patients > 65 years, 11.4 months, P = 0.129). The primary tumour receptor status was an important determinant of outcome: 31 oestrogen receptor positive (ER+)/human epidermal growth factor receptor 2 negative (HER2-) patients had a median ...Continue Reading

References

Jun 23, 2000·Annals of Surgical Oncology·K S FirlikL D Lunsford
Apr 10, 2004·Cancer·Alexander MuacevicBerndt Wowra
Jul 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jill S Barnholtz-SloanRaymond E Sawaya
Sep 21, 2004·Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]·Stephanie E CombsJürgen Debus
Jun 7, 2007·American Journal of Clinical Oncology·Serap AkyurekShiao Y Woo
Apr 7, 2009·International Journal of Radiation Oncology, Biology, Physics·Norbert KasedPenny K Sneed
Aug 1, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Florian HeitzAndreas du Bois
Nov 15, 2011·International Journal of Radiation Oncology, Biology, Physics·Jorge A CaballeroMichael W McDermott
Mar 23, 2012·International Journal of Radiation Oncology, Biology, Physics·Zhiyuan XuJason Sheehan
May 31, 2013·Radiation Oncology·Jerry J JaboinImran Zoberi
Jul 6, 2014·The Breast : Official Journal of the European Society of Mastology·C AversaF Montemurro
Sep 10, 2014·International Journal of Radiation Oncology, Biology, Physics·T Jonathan YangKathryn Beal
Feb 2, 2015·Breast Cancer Research and Treatment·Eunpi ChoVijayakrishna K Gadi
Nov 9, 2017·The New England Journal of Medicine·Hongchao PanUNKNOWN EBCTCG
Jul 23, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F CardosoE P Winer

❮ Previous
Next ❯

Citations

Aug 25, 2021·Current Treatment Options in Oncology·Eric G NesbitJonathan B Strauss

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.